**Product Data Sheet**

| | |
|---|---|
| **Product:** | PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron) (>70%) |
| **Label name:** | PepMix SARS-CoV-2 (Spike / BA.2 / Omicron) |
| **Product code:** | PM-SARS2-SMUT09-2 |
| **Source:** | SARS-CoV-2 (Severe Acute Respiratory Syndrome-Related Coronavirus 2)<br>Lineage B.1.1.529, BA.2 Omicron sub-variant<br>Spike glycoprotein - contains mutations T19I, L24-, P25-, P26-, A27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K |
| **Protein ID:** | - |
| **Gene ID:** | S |
| **No. of peptides:** | 315 peptides - 158+157 (15mers with 11 aa overlap) |
| **Amount:** | 25 µg (approx. 15 nmol) / peptide (for stimulation of up to 2,5 x $10^8$ cells) |
| **Length:** | 1270 aa |
| **Sequence:** | MFVFLVLLPL VSSQCVNLIT RTQSYTNSFT RGVYYPDKVF RSSVLHSTQD LFLPFFSNVT<br>WFHAIHVSGT NGTKRFDNPV LPFNDGVYFA STEKSNIIRG WIFGTTLDSK TQSLLIVNNA<br>TNVVIKVCEF QFCNDPFLDV YYHKNNKSWM ESEFRVYSSA NNCTFEYVSQ PFLMDLEGKQ<br>GNFKNLREFV FKNIDGYFKI YSKHTPINLG RDLPQGFSAL EPLVDLPIGI NITRFQTLLA<br>LHRSYLTPGD SSSGWTAGAA AYYVGYLQPR TFLLKYNENG TITDAVDCAL DPLSETKCTL<br>KSFTVEKGIY QTSNFRVQPT ESIVRFPNIT NLCPFDEVFN ATRFASVYAW NRKRISNCVA<br>DYSVLYNFAP FFAFKCYGVS PTKLNDLCFT NVYADSFVIR GNEVSQIAPG QTGNIADYNY<br>KLPDDFTGCV IAWNSNKLDS KVGGNYNYLY RLFRKSNLKP FERDISTEIY QAGNKPCNGV<br>AGFNCYFPLR SYGFRPTYGV GHQPYRVVVL SFELLHAPAT VCGPKKSTNL VKNKCVNFNF<br>NGLTGTGVLT ESNKKFLPFQ QFGRDIADTT DAVRDPQTLE ILDITPCSFG GVSVITPGTN<br>TSNQVAVLYQ GVNCTEVPVA IHADQLTPTW RVYSTGSNVF QTRAGCLIGA EYVNNSYECD<br>IPIGAGICAS YQTQTKSHRR ARSVASQSII AYTMSLGAEN SVAYSNNSIA IPTNFTISVT<br>TEILPVSMTK TSVDCTMYIC GDSTECSNLL LQYGSFCTQL KRALTGIAVE QDKNTQEVFA<br>QVKQIYKTPP IKYFGGFNFS QILPDPSKPS KRSFIEDLLF NKVTLADAGF IKQYGDCLGD<br>IAARDLICAQ KFNGLTVLPP LLTDEMIAQY TSALLAGTIT SGWTFGAGAA LQIPFAMQMA<br>YRFNGIGVTQ NVLYENQKLI ANQFNSAIGK IQDSLSSTAS ALGKLQDVVN HNAQALNTLV<br>KQLSSKFGAI SSVLNDILSR LDKVEAEVQI DRLITGRLQS LQTYVTQQLI RAAEIRASAN<br>LAATKMSECV LGQSKRVDFC GKGYHLMSFP QSAPHGVVFL HVTYVPAQEK NFTTAPAICH<br>DGKAHFPREG VFVSNGTHWF VTQRNFYEPQ IITTDNTFVS GNCDVVIGIV NNTVYDPLQP<br>ELDSFKEELD KYFKNHTSPD VDLGDISGIN ASVVNIQKEI DRLNEVAKNL NESLIDLQEL<br>GKYEQYIKWP WYIWLGFIAG LIAIVMVTIM LCCMTSCCSC LKGCCSCGSC CKFDEDDSEP<br>VLKGVKLHYT |
| **Purity:** | Development Grade: each peptide purified to > 70% (HPLC/MS) |
| **Appearance:** | white to off-white lyophilisate |
| **Cytotoxicity:** | No cytotoxic effects in resazurin-based cell viability assays with Jurkat cells. |
| **Remark:** | The peptides of this product are supplied as freeze-dried trifluoroacetate salts. For research use only. |
| **Storage conditions:** | Store at - 20°C |
| **Application protocol:** | https://jpt.com/support-contact/resources/application-protocols/ |

**Use recommended within 6 months**